This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stattin, P. Articles by Kaaks, R. Search for Related Content PubMed PubMed Citation Articles by Stattin, P. Articles by Kaaks, R.

Ratios of IGF-I, IGF Binding Protein-3, and Prostate-Specific Antigen in Prostate Cancer Detection

Department of Urology and Andrology (P.S.), Umeå University Hospital, 901 85 Umeå, Sweden; Department of Clinical Chemistry (U.-H.S.), Helsinki University Central Hospital, 00290 Helsinki, Finland; International Agency for Research on Cancer (E.R., R.K.), 69372 Lyon, France; and Department of Public Health and Clinical Medicine (G.H.), Umeå University Hospital, 901 85 Umeå, Sweden

Address all correspondence and requests for reprints to: Pär Stattin, Department of Urology and Andrology, Umeå University Hospital, 901 85 Umeå, Sweden. E-mail: par.stattin{at}urologi.umu.se

Abstract

Recent studies have suggested that IGF-I and IGF-binding protein (IGFBP)-3, in combination with prostate-specific antigen (PSA), may enhance prostate cancer detection. In this study, we sought to determine the effect on the prediction of future prostate cancer occurrence by incorporating ratios of total and free PSA, IGF-I, IGFBP-3 into PSA testing.

Within a population-based prospective cohort study, we investigated the validity (sensitivity and specificity) of plasma concentrations of total and free PSA, IGF-I, and IGFBP-3 and combinations thereof, in 114 cases and 97 controls, in the range of 1.75–13.5 µg/l for PSA, as used by Khosravi et al. (See Ref. 7 ).

Validity estimated by the area under the curve in receiver operator characteristics analysis (with 95% confidence interval) for total PSA was 0.78 (range, 0.71–0.84); total/free PSA, 0.69 (range, 0.62–0.76); total PSA/IGF-I, 0.72 (range, 0.65–0.79); free PSA/IGF-I, 0.55 (range, 0.48–0.63); total PSA/IGFBP-3, 0.74 (range, 0.68–0.81); and free PSA/IGFBP-3, 0.57 (range, 0.49–0.64).

Analysis of ratios of IGF-I, IGFBP-3, and free and total PSA did not improve validity of PSA testing in the prediction of future occurrence of prostate cancer. It is unlikely that these combinations will improve prostate cancer detection.

This article has been cited by other articles:

				L. Peng, P. J. Malloy, and D. Feldman Identification of a Functional Vitamin D Response Element in the Human Insulin-Like Growth Factor Binding Protein-3 Promoter Mol. Endocrinol., May 1, 2004; 18(5): 1109 - 1119. [Abstract] [Full Text] [PDF]

				A. Colao, D. Ferone, P. Marzullo, and G. Lombardi Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management Endocr. Rev., February 1, 2004; 25(1): 102 - 152. [Abstract] [Full Text] [PDF]